Comprehensive analysis of RFC4 as a potential biomarker for regulating the immune microenvironment and predicting immune therapy response in lung adenocarcinoma
RFC4 proved to be a promising biomarker for tumorigenesis and could effectively predict immunotherapy response in LUAD. RCF4 altered tumor prognosis by reshaping the TIME, and targeted inhibition of RCF4 may be a promising new strategy for treating LUAD.
Authors
- Bifen Huang
- Jian-Qing Zheng (ORCID: https://orcid.org/0000-0002-1823-1419)
- Li-hua Xiao (ORCID: https://orcid.org/0009-0008-3601-9201)
- Min Wu (ORCID: https://orcid.org/0000-0002-9666-7138)
- Bingwei Zeng
- Na Lin (ORCID: https://orcid.org/0000-0001-9630-1497)
Institutions
- Fujian Medical University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1578243
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00